Stay updated with breaking news from Iruplinalkib . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Treatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TKI–naïve, locally advanced and metastatic ALK-positive non–small cell lung cancer, according to data from a prespecified interim analysis of the phase 3 INSPIRE trial. ....